Enostosis

Description

Enostosis, also referred to as a bone island, is a benign, asymptomatic focus of compact (cortical-type) bone within cancellous (trabecular) bone. It is a developmental hamartoma rather than a neoplasm and is considered a normal variant. Enostoses are incidental findings on imaging and have no malignant potential.

The lesion represents focal failure of endochondral ossification during skeletal development, resulting in ectopic cortical bone trapped within medullary spaces. They are typically round or oval, with spiculated, radiating margins, blending with the surrounding trabeculae.

The term “enostosis” comes from Greek en- (within) and osteo- (bone), referring to its location within bone. When large, the term “giant bone island” is used (>2 cm), which can raise concern for metastasis if not recognised.

Pathogenesis

Enostoses arise due to focal retention of mature cortical bone during ossification, particularly in endochondrally formed bones. The retained bone undergoes centripetal growth, forming dense sclerotic foci within trabecular bone.

Unlike osteoblastic metastases, enostoses:

• Are non-expansile
• Do not disrupt the surrounding architecture
• Do not provoke periosteal reaction
• Do not enhance or restrict on advanced imaging

They are stable over time and usually require no intervention unless differentiation from sclerotic metastasis is difficult.

Subtypes

• Solitary enostosis – most common, single bone island
• Multiple enostoses (osteopoikilosis) – typically symmetrical, associated with sclerosing dysplasias
• Giant enostosis – rare, >2 cm in diameter

Epidemiology, Risk Factors & Associations

• Very common incidental finding (~14% prevalence on CT)
• Occur at any age; more frequent in adults
• Equal sex distribution
• No risk factors
• Associated conditions:
  • Osteopoikilosis: benign sclerosing bone dysplasia with multiple enostoses
  • Melorheostosis: may co-exist in sclerosing bone disorders
  • Sclerosing dysplasia syndromes (e.g. Buschke–Ollendorff syndrome)

Clinical Features

• Asymptomatic
• No mass effect or pain
• Found incidentally on radiographs, CT, or MRI
• No associated systemic symptoms

Complications

• None
• Very rarely, may be mistaken for osteoblastic metastases
• No risk of malignant transformation
• No risk of fracture unless misdiagnosed and subjected to unnecessary biopsy or intervention

Pathological Features

Histopathology

• Macroscopic:
  • Dense, ivory-like area within cancellous bone
• Microscopic:
  • Mature lamellar bone with haversian systems
  • No cellular atypia, mitosis, or marrow elements
  • Seamlessly blends into surrounding trabecular bone

Serology

• Not applicable

Biochemistry

• Normal calcium, phosphate, alkaline phosphatase

Immunohistochemistry

• Not required

Molecular

• No molecular abnormalities

Genetics

• Solitary enostoses are not inherited
• Multiple enostoses (osteopoikilosis) follow autosomal dominant inheritance with variable penetrance (e.g. LEMD3 mutations)

Radiological Features

General Features

• Well-defined, homogeneous sclerotic lesion within trabecular bone
• Typically <2 cm, round or oval
• Characteristic spiculated radiating margins that blend with surrounding trabeculae (brush border or thorny radiations)
• No cortical destruction, periosteal reaction, or soft tissue mass
• Most commonly located in:
  • Pelvis, femur, sacrum, spine, humerus
• Lesions are stable over years
• No uptake on bone scan or minimal, unlike metastases

XR

• Small, dense sclerotic foci
• Brush border or feathered edge within cancellous bone
• No periosteal reaction
• Common sites: pelvis, proximal femur, vertebrae

CT

• Dense intramedullary focus with attenuation similar to cortical bone (800–1200 HU)
• Radiating spicules into trabecular bone
• No endosteal scalloping or cortical thinning
• No contrast enhancement
• Useful for differentiating from metastasis or sclerosis from prior trauma

MRI

• T1:
  • Low signal intensity (hypointense), similar to cortical bone
  • Uniform, sharply marginated
• T2:
  • Low signal intensity
  • May have surrounding marrow fat
• STIR:
  • No signal change (i.e. no surrounding oedema)
• DWI/ADC:
  • No diffusion restriction
• Post-contrast:
  • No enhancement
  • Absence of reactive marrow changes

US

• Not applicable

NM

• Bone scan:
  • Typically cold or non-avid
  • Occasionally faint uptake (due to surrounding trabecular remodelling)
  • Differentiates from osteoblastic metastases (which are typically hot)

Associated Findings

• In osteopoikilosis: multiple, symmetric, small enostoses involving epiphyses and metaphyses of long bones
• No soft tissue component
• No bone expansion
• Stable on serial imaging

Grading and Staging

• No grading or staging system
• Described based on:
  • Size (giant enostosis >2 cm)
  • Number (solitary vs multiple)
  • Distribution (generalised in osteopoikilosis)

Diagnosis

• Based on classic imaging features
• No biopsy required if characteristic:
  • Spiculated brush border
  • Homogeneous sclerosis
  • No soft tissue mass
  • Stability over time
• Bone scan or MRI may be used if concern for metastasis

Differential Diagnosis

Image-based

• Osteoblastic metastasis:
  • Often irregular, heterogenous, cortical involvement
  • Hot on bone scan
  • Common in prostate, breast, bladder cancers
• Blastic bone island vs sclerotic haemangioma (vertebra):
  • Haemangioma shows vertical striations and high T1 signal due to fat
• Bone infarct:
  • Serpiginous peripheral sclerosis
  • Central fat signal and variable enhancement
• Osteoma:
  • Arises from cortex or periosteum, not medulla
  • Usually on skull or facial bones

Clinically-based

• Sclerotic lesion in known cancer patient (must distinguish from metastasis)
• Bone pain of unclear origin (if coincidental enostosis)
• Unexplained sclerosis on imaging (post-traumatic, infectious, metabolic)

Management

• No treatment required – don’t touch lesion
• Reassurance and documentation
• Avoid unnecessary biopsy
• If atypical features:
  • Follow-up imaging
  • Bone scan or MRI to exclude metastasis
• In multiple lesions (osteopoikilosis):
  • Evaluate for syndromic features (skin, connective tissue disorders)
• Imaging follow-up may be performed at 6–12 months to confirm stability if uncertain